Comparative Pharmacology
Head-to-head clinical analysis: SULF 10 versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 10 versus SULFALAR.
SULF-10 vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)